National Vision (EYE) vs STAAR Surgical (STAA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
STAAR Surgical (STAA) has outperformed National Vision (EYE) over the past year, losing 13.5% versus a loss of 37.1%. Over five years, EYE leads with a -65.0% price change compared with -75.1% for STAA. National Vision is the larger company by market cap ($1.31 billion vs $1.22 billion), about 1.1 times the size.
On valuation, National Vision trades at a lower forward P/E (14.3x vs 21.4x for STAAR Surgical). National Vision converts more of its revenue into profit, with a net margin of 1.5% versus -33.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYE | STAA |
|---|---|---|
| Share price | $16.72 | $24.22 |
| Market cap | $1.31B | $1.22B |
| 1-day change | -1.70% | -3.24% |
| YTD return | -35.24% | +4.89% |
| 1-year return | -37.12% | -13.50% |
| 5-year return | -65.00% | -75.08% |
| P/E ratio (TTM) | 20.39 | — |
| Forward P/E | 14.31 | 21.39 |
| EPS (TTM) | $0.82 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.99B | $239.44M |
| Revenue growth (YoY) | +9.00% | -23.72% |
| Net income (latest FY) | $29.60M | $-80.45M |
| Gross margin | 58.77% | 76.19% |
| Operating margin | 2.96% | -38.30% |
| Net margin | 1.49% | -33.60% |
| 52-week high | $30.02 | $35.87 |
| 52-week low | $14.75 | $15.59 |
| Distance from 52-week high | -44.30% | -32.48% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +61.48% | +17.92% |
| Average volume | 2.14M | 835.89K |
| Shares outstanding | 78.07M | 50.20M |
| Employees | 13,138 | 921 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STAA has outperformed EYE by 23.6 percentage points over the past year.
- National Vision is more profitable, keeping 1.5 cents of every revenue dollar as net income versus -33.6 cents for STAAR Surgical.
- National Vision grew revenue faster in its latest fiscal year (+9.00% vs -23.72%).
About National Vision
EYE stock →National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company offers eyeglasses and contact lenses, and optical accessory products; and provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, Vista Optical military, and DiscountContacts.com.
Health Care · Ophthalmic Goods · 13,138 employees
About STAAR Surgical
STAA stock →STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Health Care · Ophthalmic Goods · 921 employees
EYE vs STAA FAQ
Which is bigger, National Vision or STAAR Surgical?
National Vision (EYE) is larger, with a market capitalization of $1.31B compared with $1.22B for STAAR Surgical (STAA).
Which stock has performed better over the past year, EYE or STAA?
STAA returned -13.50% over the past 12 months, compared with -37.12% for EYE (price return, excluding dividends). Past performance does not predict future results.
Are National Vision and STAAR Surgical in the same industry?
Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.